Microvast Holdings announces departure of chief financial officer
Shattuck Labs Inc (STTK) stock has tumbled to a 52-week low, reaching a price level of just $0.93. This significant drop reflects a stark 1-year change, with the company’s stock value plummeting by -89.09%. According to InvestingPro data, the stock currently trades at just 0.57 times book value, suggesting potential undervaluation despite its weak financial health score of 1.62 out of 5. Investors have watched with concern as Shattuck Labs, a clinical-stage biotechnology company, has faced a challenging market environment, leading to a steep decline in its stock price over the past year. The current low represents a critical moment for the company as it navigates through its financial and operational hurdles. While the company maintains a strong current ratio of 8.88 and holds more cash than debt, analysts have revised their earnings expectations downward. InvestingPro subscribers can access 12 additional key insights and detailed analyst forecasts to better understand the company’s prospects.
In other recent news, Shattuck Labs reported its fourth-quarter and full-year 2024 financial results, revealing a fourth-quarter earnings per share (EPS) of ($0.37) and an annual EPS of ($1.49), both of which surpassed the consensus estimates. The company ended 2024 with $73 million in cash reserves, expected to fund operations through 2027. Leerink Partners initiated coverage on Shattuck Labs with an Outperform rating and set a price target of $4.00, citing the company’s strategic focus on inflammatory bowel disease (IBD) as a promising direction.
Shattuck Labs has announced encouraging preclinical results for its drug candidate SL-325, intended for IBD treatment, demonstrating no evidence of toxicity in non-human primates. The company plans to file an Investigational New Drug (IND) application for SL-325 in the third quarter of 2025. H.C. Wainwright reaffirmed a Neutral rating on Shattuck Labs, reflecting a cautious stance despite the company’s financial performance exceeding expectations. The upcoming Phase 1 clinical trial for SL-325 is slated to begin later in 2025, with data from a GLP toxicology study expected in the first quarter of the year. Shattuck Labs is also preparing for presentations at various industry conferences, including the European Crohn’s and Colitis Organization Congress and the J.P. Morgan Healthcare Conference.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.